|[April 14, 2014]
Research and Markets: Global Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/tb2h6k/infanrix_hexa)
has announced the addition of the "Infanrix
Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market
Analysis to 2022" report to their offering.
Infanrix Hexa [Diphtheria, tetanus, pertussis (acellular, component),
hepatitis B (rDNA), inactivated poliovirus, Hib conjugate vaccine
(adsorbed)] is GSK's hexavalent combination vaccine that offers
protection against infections caused by diphtheria, tetanus, pertussis,
three subtypes of poliovirus, Hib, and all nown subtypes of HBV.
Infanrix Hexa contains the antigenic components used in GSK's Pediarix
[diphtheria toxoid, tetanus toxoid, inactivated pertussis toxin (PT),
filamentous hemagglutinin (FHA), pertactin, and inactivated poliovirus
subtypes Mahoney, MEF (News - Alert)-1, and Saukett, and yeast-derived HBsAg] and
Hiberix (Hib capsular polysaccharide PRP) vaccines (Hiberix package
insert, 2012; Pediarix package insert, 2012).
Overview of Hepatitis B disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Infanrix Hexa including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Infanrix Hexa for top six countries from 2012 to
Sales information covered for the US, France, Germany, Italy, Spain
Key Topics Covered:
Tables & Figures
Vaccination Recommendations and Coverage Rates
For more information visit http://www.researchandmarkets.com/research/tb2h6k/infanrix_hexa
[ InfoTech Spotlight's Homepage ]